Published in Eur Respir J on May 01, 2011
Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J (2012) 2.17
Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones. Eur Respir J (2012) 0.94
New anti-tuberculosis drugs and regimens: 2015 update. ERJ Open Res (2015) 0.83
Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA (1999) 27.82
cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci U S A (1996) 16.69
Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med (1998) 10.78
WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J (2011) 8.96
Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA (2000) 8.42
Global tuberculosis incidence and mortality during 1990-2000. Bull World Health Organ (1994) 6.11
Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med (2001) 6.05
Zoonotic tuberculosis due to Mycobacterium bovis in developing countries. Emerg Infect Dis (1998) 5.51
Interferon-γ release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur Respir J (2010) 4.72
Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. International Union Against Tuberculosis and Lung Disease. Clin Infect Dis (1997) 4.02
HIV-associated tuberculosis in developing countries: epidemiology and strategies for prevention. Tuber Lung Dis (1992) 3.95
Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J (2010) 3.81
125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is "science" enough to tackle the epidemic? Eur Respir J (2007) 3.67
Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis (2001) 3.51
LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J (2009) 3.16
Public health. Responding to market failures in tuberculosis control. Science (2001) 3.12
Structure at 2.3 A resolution of the cytochrome bc(1) complex from the yeast Saccharomyces cerevisiae co-crystallized with an antibody Fv fragment. Structure (2000) 3.03
A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J (2009) 2.92
A heat shock following electroporation induces highly efficient transformation of Corynebacterium glutamicum with xenogeneic plasmid DNA. Appl Microbiol Biotechnol (1999) 2.58
The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J (2010) 2.56
Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J (2007) 2.46
Induction of host signal transduction pathways by Helicobacter pylori. Proc Natl Acad Sci U S A (1997) 2.38
Tuberculosis contact investigation in low prevalence countries: a European consensus. Eur Respir J (2010) 2.38
Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur Respir J (2008) 2.23
Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). JAMA (1995) 2.08
Relationship of immunodiagnostic assays for tuberculosis and numbers of circulating CD4+ T-cells in HIV infection. Eur Respir J (2009) 2.07
Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis (1993) 2.07
Tuberculosis control in Europe and international migration. Eur Respir J (1994) 2.07
Cost-effectiveness analysis of invasive and noninvasive tests in high risk patients treated with amiodarone after acute myocardial infarction. J Am Coll Cardiol (1998) 2.02
Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J (2009) 2.01
Involvement of tissue bacteria in the onset of diabetes in humans: evidence for a concept. Diabetologia (2011) 2.00
Progress in global tuberculosis control 1995-1996, with emphasis on 22 high-incidence countries. Global Monitoring and Surveillance Project. Int J Tuberc Lung Dis (1999) 1.90
Frequency of recurrence among MDR-tB cases 'successfully' treated with standardised short-course chemotherapy. Int J Tuberc Lung Dis (2002) 1.86
Local immunodiagnosis of pulmonary tuberculosis by enzyme-linked immunospot. Eur Respir J (2007) 1.81
Treatment of tuberculosis: update 2010. Eur Respir J (2010) 1.79
CD8 T cells specific for human immunodeficiency virus, Epstein-Barr virus, and cytomegalovirus lack molecules for homing to lymphoid sites of infection. Blood (2001) 1.74
European union standards for tuberculosis care. Eur Respir J (2012) 1.73
Drug-resistant tuberculosis: laboratory issues. World Health Organization recommendations. Tuber Lung Dis (1994) 1.71
[Sociodemographic characteristics in the German Health Interview and Examination Survey for Children and Adolescents (KiGGS) - operationalisation and public health significance, taking as an example the assessment of general state of health]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz (2007) 1.71
Search for supersymmetry using final states with one lepton, jets, and missing transverse momentum with the ATLAS detector in √s=7 TeV pp collisions. Phys Rev Lett (2011) 1.60
High risk of tuberculosis in health care workers in Romania. Int J Tuberc Lung Dis (2008) 1.60
Proteins encoded by the cag pathogenicity island of Helicobacter pylori are required for NF-kappaB activation. Infect Immun (1998) 1.58
Cost-effectiveness of treating latent tuberculous infection: a step towards elimination? Int J Tuberc Lung Dis (2013) 1.58
Comparison of two methods of processing induced sputum: selected versus entire sputum. Am J Respir Crit Care Med (1998) 1.56
Cost-optimisation of screening for latent tuberculosis in close contacts. Eur Respir J (2006) 1.55
Tuberculosis contact investigation with a new, specific blood test in a low-incidence population containing a high proportion of BCG-vaccinated persons. Respir Res (2006) 1.54
Impact of the HIV epidemic on the spread of other diseases: the case of tuberculosis. AIDS (2000) 1.52
Characterization of a Flavobacterium glutathione S-transferase gene involved reductive dechlorination. J Bacteriol (1993) 1.50
Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre. AIDS (1995) 1.48
Univariate and multivariate family-based association analysis of the IL-13 ARG130GLN polymorphism in the Childhood Asthma Management Program. Genet Epidemiol (2002) 1.46
Standardization of antituberculosis drug resistance surveillance in Europe. Recommendations of a World Health Organization (WHO) and International Union Against Tuberculosis and Lung Disease (IUATLD) Working Group. Eur Respir J (2000) 1.45
Use of a T-cell interferon-gamma release assay for the diagnosis of tuberculous pleurisy. Eur Respir J (2007) 1.44
Tuberculosis management in Europe. Task Force of the European Respiratory Society (ERS), the World Health Organisation (WHO) and the International Union against Tuberculosis and Lung Disease (IUATLD) Europe Region. Eur Respir J (1999) 1.42
Observation of a centrality-dependent dijet asymmetry in lead-lead collisions at sqrt[S(NN)] =2.76 TeV with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.41
Induced sputum cellularity. Reference values and distribution in normal volunteers. Am J Respir Crit Care Med (2000) 1.40
Prospective management of a child with neonatal citrullinemia. J Pediatr (1993) 1.39
Measurement of dijet azimuthal decorrelations in pp collisions at sqrt(s)=7 TeV. Phys Rev Lett (2011) 1.39
[Infection diagnostics in pneumology. Part 1. Survey and methods]. Pneumologie (2008) 1.38
Induced sputum to assess airway inflammation: a study of reproducibility. Clin Exp Allergy (1997) 1.35
Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. Am J Respir Crit Care Med (1994) 1.35
Determination of the strange-quark density of the proton from ATLAS measurements of the W→ℓν and Z→ℓℓ cross sections. Phys Rev Lett (2012) 1.34
Search for new particles in two-jet final states in 7 TeV proton-proton collisions with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.32
Determinants of child nutrition and mortality in north-west Uganda. Bull World Health Organ (1992) 1.32
Once-weekly rifapentine-containing regimens for treatment of tuberculosis in mice. Am J Respir Crit Care Med (1998) 1.30
TB and MDR/XDR-TB in European Union and European Economic Area countries: managed or mismanaged? Eur Respir J (2012) 1.29
[Health monitoring at the Robert Koch Institute. Status and perspectives]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz (2009) 1.28
Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection. Eur Respir J (2009) 1.27
Observation of associated near-side and away-side long-range correlations in sqrt[s(NN)]=5.02 TeV proton-lead collisions with the ATLAS detector. Phys Rev Lett (2013) 1.27
Diagnosis and treatment of tuberculosis in undocumented migrants in low- or intermediate-incidence countries. Int J Tuberc Lung Dis (2008) 1.27
Validation of the surveillance system for new cases of tuberculosis in a province of northern Italy. Varese Tuberculosis Study Group. Eur Respir J (1995) 1.25
Rapid diagnosis of Mycobacterium tuberculosis meningitis by enumeration of cerebrospinal fluid antigen-specific T-cells. Int J Tuberc Lung Dis (2008) 1.24
Primary lymphoma of the liver. Cancer (1988) 1.24
Tuberculosis and noncommunicable diseases: neglected links and missed opportunities. Eur Respir J (2010) 1.24
Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients. Eur Respir J (2006) 1.22
Tuberculosis in HIV-infected persons in the context of wide availability of highly active antiretroviral therapy. Eur Respir J (2004) 1.21
Search for dark matter candidates and large extra dimensions in events with a photon and missing transverse momentum in pp collision data at sqrt[s]=7 TeV with the ATLAS detector. Phys Rev Lett (2013) 1.19
Practical way to assess metabolic syndrome using a continuous score obtained from principal components analysis. Diabetologia (2006) 1.19
Improving the TB case management: The International Standards for Tuberculosis Care. Eur Respir J (2006) 1.19
Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)? Int J Tuberc Lung Dis (2001) 1.18
A secreted/shed product of Helicobacter pylori activates transcription factor nuclear factor-kappa B. J Immunol (1997) 1.17
Drug resistant tuberculosis among the homeless in New York City. N Y State J Med (1990) 1.17
TB and M/XDR-TB infection control in European TB reference centres: the Achilles' heel? Eur Respir J (2011) 1.16